These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

380 related items for PubMed ID: 23241507

  • 1. Rash to the mTOR inhibitor everolimus: systematic review and meta-analysis.
    Ramirez-Fort MK, Case EC, Rosen AC, Cerci FB, Wu S, Lacouture ME.
    Am J Clin Oncol; 2014 Jun; 37(3):266-71. PubMed ID: 23241507
    [Abstract] [Full Text] [Related]

  • 2. Incidence and risk of rash to mTOR inhibitors in cancer patients--a meta-analysis of randomized controlled trials.
    Shameem R, Lacouture M, Wu S.
    Acta Oncol; 2015 Jan; 54(1):124-32. PubMed ID: 24914484
    [Abstract] [Full Text] [Related]

  • 3. Hematologic toxicities associated with mTOR inhibitors temsirolimus and everolimus in cancer patients: a systematic review and meta-analysis.
    Xu J, Tian D.
    Curr Med Res Opin; 2014 Jan; 30(1):67-74. PubMed ID: 24028709
    [Abstract] [Full Text] [Related]

  • 4. Risk of anemia attributable to everolimus in patients with cancer: a meta-analysis of randomized controlled trials.
    Shameem R, Hamid MS, Wu S.
    Anticancer Res; 2015 Apr; 35(4):2333-40. PubMed ID: 25862897
    [Abstract] [Full Text] [Related]

  • 5. Incidence and risk of high-grade stomatitis with mTOR inhibitors in cancer patients.
    Shameem R, Lacouture M, Wu S.
    Cancer Invest; 2015 Mar; 33(3):70-7. PubMed ID: 25635371
    [Abstract] [Full Text] [Related]

  • 6. Treatment-related fatigue with everolimus and temsirolimus in patients with cancer-a meta-analysis of clinical trials.
    Peng L, Zhou Y, Ye X, Zhao Q.
    Tumour Biol; 2015 Feb; 36(2):643-54. PubMed ID: 25281033
    [Abstract] [Full Text] [Related]

  • 7. The risk of rash associated with ipilimumab in patients with cancer: a systematic review of the literature and meta-analysis.
    Minkis K, Garden BC, Wu S, Pulitzer MP, Lacouture ME.
    J Am Acad Dermatol; 2013 Sep; 69(3):e121-8. PubMed ID: 23357570
    [Abstract] [Full Text] [Related]

  • 8. Risk of rash in cancer patients treated with vandetanib: systematic review and meta-analysis.
    Rosen AC, Wu S, Damse A, Sherman E, Lacouture ME.
    J Clin Endocrinol Metab; 2012 Apr; 97(4):1125-33. PubMed ID: 22378813
    [Abstract] [Full Text] [Related]

  • 9. The risk of skin rash and stomatitis with the mammalian target of rapamycin inhibitor temsirolimus: a systematic review of the literature and meta-analysis.
    Gomez-Fernandez C, Garden BC, Wu S, Feldman DR, Lacouture ME.
    Eur J Cancer; 2012 Feb; 48(3):340-6. PubMed ID: 22206873
    [Abstract] [Full Text] [Related]

  • 10. Incidence and risk of treatment-related mortality with mTOR inhibitors everolimus and temsirolimus in cancer patients: a meta-analysis.
    Qi WX, Huang YJ, Yao Y, Shen Z, Min DL.
    PLoS One; 2013 Feb; 8(6):e65166. PubMed ID: 23785409
    [Abstract] [Full Text] [Related]

  • 11. Attributable Risk of Infection to mTOR Inhibitors Everolimus and Temsirolimus in the Treatment of Cancer.
    Garcia CA, Wu S.
    Cancer Invest; 2016 Nov 25; 34(10):521-530. PubMed ID: 27791402
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Incidence and risk of treatment-related mortality in cancer patients treated with the mammalian target of rapamycin inhibitors.
    Choueiri TK, Je Y, Sonpavde G, Richards CJ, Galsky MD, Nguyen PL, Schutz F, Heng DY, Kaymakcalan MD.
    Ann Oncol; 2013 Aug 25; 24(8):2092-7. PubMed ID: 23658373
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Metabolic complications with the use of mTOR inhibitors for cancer therapy.
    Sivendran S, Agarwal N, Gartrell B, Ying J, Boucher KM, Choueiri TK, Sonpavde G, Oh WK, Galsky MD.
    Cancer Treat Rev; 2014 Feb 25; 40(1):190-6. PubMed ID: 23684373
    [Abstract] [Full Text] [Related]

  • 17. Everolimus.
    Hasskarl J.
    Recent Results Cancer Res; 2014 Feb 25; 201():373-92. PubMed ID: 24756805
    [Abstract] [Full Text] [Related]

  • 18. Everolimus: side effect profile and management of toxicities in breast cancer.
    Paplomata E, Zelnak A, O'Regan R.
    Breast Cancer Res Treat; 2013 Aug 25; 140(3):453-62. PubMed ID: 23907751
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.